Literature DB >> 23640634

Acute renal failure by ingestion of Euphorbia paralias.

Karima Boubaker1, Mondher Ounissi, Nozha Brahmi, Rym Goucha, Hafedh Hedri, Taieb Ben Abdellah, Fethi El Younsi, Hedi Ben Maiz, Adel Kheder.   

Abstract

Euphorbia paralias is known in traditional medicine as an anti-inflammatory agent, a purgative and for its local anesthetic property. To the best our knowledge, renal toxicity of this substance has not been previously reported. In this paper, we report the case of a 29-year-old male who developed renal damage following ingestion of Euphorbia paralias. He had been on follow-up for nephrotic syndrome since 1986, although irregularly, with several relapses but each responding well to steroid therapy. A kidney biopsy had not been performed earlier due to refusal by the patient. He was off steroids since April 2008 because the patient developed osteoporosis. He was admitted with general malaise and oliguria to our department in May 2009, following repeated vomiting and watery diarrhea for three days. On examination, he was edematous but had normal vital signs except for a pulse rate of 120/min. Hemoglobin was only 5.5 g/dL but with normal white cell and platelet counts. Blood biochemistry showed evidence of advanced renal failure with a serum creatinine level of 1835 μmol/L and urea at 44.6 mmol/L, sodium of 132 μmol/L and potassium at 4.3 mmol/L. He had features of nephrotic syndrome with severe hypoproteinamia and 24-h urinary protein of 10.45 g. Ultrasonography revealed enlarged kidneys with a reduced echogenecity of the medulla and the papillae. Subsequently, after hemodialysis with blood transfusion, a kidney biopsy was performed that showed focal segmental glomerulosclerosis associated with an acute tubular injury. On intensive interrogation, the patient gave a history of ingesting boiled Euphorbia paralias as a native treatment for edema, ten days prior to the onset of the current illness. A diagnosis of acute renal failure (ARF) resulting from the possible nephrotoxic effect of Euphorbia paralias poisoning was made. He was treated with intermittent hemodialysis and corticosteroids. Serum creatinine values improved after 48 days. At six months following the intoxication, serum creatinine of the patient was 240 μmol/L. In cases of unexplained ARF, a toxic mechanism should always be considered and acute renal failure caused by Euphorbia paralias should be included as a cause if renal toxicity is suspected in those places where it is being used as a native medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23640634     DOI: 10.4103/1319-2442.111069

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  4 in total

Review 1.  Nephrotoxicity and Chinese Herbal Medicine.

Authors:  Bo Yang; Yun Xie; Maojuan Guo; Mitchell H Rosner; Hongtao Yang; Claudio Ronco
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-03       Impact factor: 8.237

2.  Investigation of the In-Vivo Cytotoxicity and the In Silico-Prediction of MDM2-p53 Inhibitor Potential of Euphorbia peplus Methanolic Extract in Rats.

Authors:  Yasmina M Abd-Elhakim; Mohamed Abdo Nassan; Gamal A Salem; Abdelkarim Sasi; Adil Aldhahrani; Khaled Ben Issa; Amany Abdel-Rahman Mohamed
Journal:  Toxins (Basel)       Date:  2019-11-04       Impact factor: 4.546

3.  Nephroprotective, cytotoxic and antioxidant activities of Euphorbia paralias.

Authors:  Hanan M Al-Yousef; Ali S Alqahtani; Afaf S A Ghani; Sayed A El-Toumy; Wagdi I A El-Dougdoug; Wafaa H B Hassan; Hanaa M Hassan
Journal:  Saudi J Biol Sci       Date:  2020-11-11       Impact factor: 4.219

4.  Aqueous Bark Extract of Ceiba speciosa (A. St.-Hill) Ravenna Protects against Glucose Toxicity in Caenorhabditis elegans.

Authors:  Fabrine Bianchin Dos Santos; Caroline Brandão Quines; Luiz Eduardo Ben Pilissão; Ana Helena de Castro Dal Forno; Cristiane Freitas Rodrigues; Cristiane Casagrande Denardin; Fabiane Moreira Farias; Daiana Silva Ávila
Journal:  Oxid Med Cell Longev       Date:  2020-10-08       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.